ClinicalTrials.Veeva

Menu
H

Hospital Privado de Comunidad | Clinical Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Abiraterone Acetate
Prednisone Versus Abiraterone Acetate
Nivolumab
Niraparib
Prednisone
Erdafitinib
Tivozanib
Ibrutinib
Vinflunine
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 26 total trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting
Urothelial Cancer
Drug: Erdafitinib
Drug: Docetaxel

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with...

Active, not recruiting
Advanced Solid Tumor
Drug: Erdafitinib

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Niraparib
Drug: Prednisone

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Prednisone
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have...

Active, not recruiting
Renal Cell Carcinoma
Drug: Tivozanib
Drug: Nivolumab

Trial sponsors

H
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
AVEO Pharmaceuticals logo
Bristol-Myers Squibb (BMS) logo
Loxo Oncology logo
Roche logo
H

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems